Synapse - Works

Results (2639)

Validation of the PRIMA-prognostic index for patients treated with rituximab plus chemotherapy and refinement of prognostic parameters for patients on rituximab plus lenalidomide in the phase III relevance trial

Meeting Abstract

Julia, E.; Fowler, N. H.; Bachy, E.; Feugier, P.; Bouabdallah, R.; Tilly, H.; Palomba, M. L.; Fruchart, C.; Libby, E. N. 3rd; Casasnovas, R. O.; more...
Blood (2019)

Fulltext@MSK | Save

Hematological count recovery in patients undergoing treatment with chimeric antigen receptor T cells (CAR T)

Meeting Abstract

Jain, T.; Knezevic, A.; Pennisi, M.; Ruiz, J. D.; Devlin, S. M.; Maloy, M. A.; Halton, E.; Diamonte, C.; Scordo, M.; Sauter, C. S.; more...
Blood (2019)

Fulltext@MSK | Save

Early experience using radiotherapy as a salvage treatment for relapsed or refractory non-Hodgkin lymphomas following CD19 chimeric antigen receptor modified T-cell therapy

Meeting Abstract

Imber, B.; Palomba, M. L.; DeSelm, C.; Dahi, P. B.; Sauter, C. S.; Scordo, M.; Batlevi, C. L.; Park, J. H.; Shah, G. L.; Giralt, S. A.; more...
Blood (2019)

Fulltext@MSK | Save

MSKCC early experience using radiotherapy as a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy

Meeting Abstract

Imber, B.; Palomba, M. L.; DeSelm, C.; Batlevi, C. L.; Dahi, P. B.; Giralt, S. A.; Noy, A.; Park, J. H.; Sauter, C. S.; Scordo, M.; more...
Blood (2019)

Fulltext@MSK | Save

Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: Selection of regimen for the dose-expansion phase

Meeting Abstract

Horwitz, S. M.; Mehta-Shah, N.; Pro, B.; Jacobsen, E. D.; Casulo, C.; Brammer, J. E.; Haney, J.; Youssoufian, H.; Weaver, D. T.; Baglio, M.; more...
Blood (2019)

Fulltext@MSK | Save

Pharmacodynamic effects and immune correlates of response to the CD20/cd3 bispecific antibody mosunetuzumab in relapsed or refractory non-Hodgkin lymphoma

Meeting Abstract

Hernandez, G.; Huw, L. Y.; Belousov, A.; Wilson, D.; Koeppen, H.; McCord, R.; Peng, K.; Bartlett, N. L.; Budde, L. E.; Assouline, S.; more...
Blood (2019)

Fulltext@MSK | Save

Monotherapy activity with the first CD20-targeted immunotoxin, MT-3724, in subjects with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Hamlin, P. A.; Musteata, V.; Zodelava, M.; Park, S. I.; Burnett, C.; Dabovic, K.; Williams, E. T.; Higgins, J. P.; Persky, D. O.
Blood (2019)

Fulltext@MSK | Save

Incidence of delayed seromas and related risk of BIA-ALCL in a cohort of 3521 breast cancer women with textured implants prospectively followed long term

Meeting Abstract

Ghione, P.; Cordeiro, P.; Seshan, V.; Galasso, N.; Ganesan, N.; Hu, Q.; Dogan, A.; Horwitz, S. M.
Blood (2019)

Fulltext@MSK | Save

Contemporary outcomes in HTLV-1-associated adult T-cell leukemia/lymphoma: Single-institution experience

Meeting Abstract

Epstein-Peterson, Z. D.; Ghione, P.; Moskowitz, A. J.; Dahi, P. B.; Dogan, A.; Kumar, A.; Matasar, M. J.; Noy, A.; Perales, M. A.; Ponce, D. M.; more...
Blood (2019)

Fulltext@MSK | Save

An individualized risk mitigation approach for safety: Experience from the mosunetuzumab (CD20/CD3 bispecific antibody) development program in relation to neurotoxicity risk

Meeting Abstract

Diefenbach, C.; Assouline, S.; Bosch, F.; Cheah, C. Y.; Kim, W. S.; Matasar, M. J.; Panizo, C.; Yoon, D. H.; Bender, B.; Hernandez, G.; more...
Blood (2019)

Fulltext@MSK | Save